RANGER II SFA PIVOTAL TRIAL1

Prospective, Multi-Center, Randomized Controlled Trial Ranger Drug-Coated Balloon vs. Uncoated Balloon (3:1).

Follow-up through 5 years

 

Ranger demonstrated nearly 90% K-M primary patency at 12 months

line
12-Month Primary Patency
 

Primary safety endpoint was freedom from MAE and primary effectiveness endpoint was binary primary patency.

PRIMARY ENDPOINTS RANGER PTA p-value
Primary Safety Endpoint
(Freedom from MAE)
94.1%
(241/256)
83.5%
(76/91)
Pnon-inferiority<0.0001
Primary Effectiveness Endpoint
(Binary Primary Patency)
82.9%
(194/234)
66.3%
(57/86)
0.0017
 

Clinically Driven TLR (CD-TLR) & Mortality

Ranger demonstrated significantly lower CD-TLR and no difference in mortality vs. PTA at 12 months.

CD-TLR and Mortality charts

Ranger PK Substudy5

 
Ranger PK Substudy

Study Method

  • Designed to evaluate the levels of paclitaxel in the systemic circulation of 12 subjects who were treated with Ranger DCB
  • Protocol required blood draws: Baseline, 10 minutes, 30 minutes, 1, 3, 6, 24 or 48 hours, 7 days and 30 days after last Ranger DCB treatment and removal
  • The limit of quantification was defined as < 1 ng/mL
  • Average number of DCBs used per patient: 1.75
 
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top